Jigna Shah

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

S. Chandarlapaty, C. Hudis, C. Swanton, 2013, Breast Cancer Research.

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.

Sung-Bae Kim, S. Loi, R. Salgado, 2020, The Lancet. Oncology.

UNDERSTANDING TRIPLE NEGATIVE BREAST CANCER: A REVIEW ON MOLECULAR SIGNALING PATHWAYS

P. Patel, J. Shah, Jigna Shah, 2020, International Journal of Pharmaceutical Sciences and Drug Research.

TGF-β at the crossroads of multiple prognosis in breast cancer, and beyond.

J. Shah, Ankit Naik, Nirali Shukla, 2022, Life sciences.

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

E. Winer, P. Ellis, Chiun-Sheng Huang, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

S. Loi, F. Esteva, C. Saura, 2019, Annals of Oncology.